Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preventing future cancers by testing women with ovarian cancer for BRCA mutations.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Feb 2010

Kwon Janice S, Daniels Molly S, Sun Charlotte C, Lu Karen H

Abstract excerpt

PURPOSE: Women with ovarian cancer have a 10% probability of carrying a BRCA mutation. If a mutation is identified, unaffected family members can undergo genetic testing and cancer risk-reducing strategies. We estimated the net health benefits and cost-effectiveness of different criteria for BRCA mutation testing in women with ovarian cancer, and the downstream benefits for their first-degree relatives (FDRs)....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cost-Benefit Analysis

Share to Cystadenocarcinoma, Serous

Share to Markov Chains

Share to Neoplasm Invasiveness

Share to Ovarian Neoplasms

Share to Survival Rate

Source

Identifiers

PMID: 19841329
DOI: 10.1200/JCO.2008.21.4684

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preventing future cancers by testing women with ovarian cancer for BRCA mutations.PMID 19841329Read ↗

Cost-effectiveness of population-based BRCA1/2 testing and ovarian cancer prevention for Ashkenazi Jews: a call for dialogue.Semantic proximity Read ↗

Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.Semantic proximity Read ↗

Expanding the criteria for BRCA mutation testing in breast cancer survivors.Semantic proximity Read ↗

Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.Semantic proximity Read ↗

A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.Semantic proximity Read ↗

A discrete event simulation to evaluate the cost effectiveness of germline <i>BRCA1</i> and <i>BRCA2</i> testing in UK women with ovarian cancerSemantic proximity Read ↗

A model for estimating ovarian cancer risk: application for preventive oophorectomy.Semantic proximity Read ↗

Cost-Effectiveness of Population-Based Multigene Testing for Breast and Ovarian Cancer PreventionSemantic proximity Read ↗

Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: a decision analysis.Semantic proximity Read ↗

Current detection rates and time-to-detection of all identifiable BRCA carriers in the Greater London population.Semantic proximity Read ↗

The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2.Semantic proximity Read ↗

Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in BRCA1 or BRCA2.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.